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The syndrome of ischemic necrosis of the anterior 
pituitary gland subsequent to postpartum hemorrhage was 
first described by the British pathologist, H.L. Sheehan, 
in 1937! Sheehan stated that the causal relationship 
of postpartum hemorrhage to anterior pituitary necrosis 
was first suggested by the coincidental autopsy findings 
of pituitary necrosis in two patients who had chronic 
hypopituitarism: 
"The first case was a woman aged 35, who had attacks of 
hypoglycemia and had a laparotomy for suspected pancreatic 
tumor. At autopsy two days later we found that the 
anterior lobe was replaced by a thin layer of fibrous 
tissue. She had been ill since her last baby was born, 
but we did not check her obstetric history! The second 
case was a woman who died of unexplained shock two hours 
after delivery. At autopsy, we found that her pituitary 
was reduced to a small patch in front of the stalk; 
all the rest was fibrous scar. She had nearly died at the 
previous delivery two years before; the cause was retained 
placenta with severe hemorrhage. These two cases of 
chronic hypopituitarism suggested that the original lesion 
leading to scarring of the anterior lobe might be found 
in obstetric patients. So we examined the pituitary in 
all obstetric autopsies and found a number of fresh 
necroses of the anterior lobe." 
Sheehan wrote that as of 1937, about 60 cases of anterior 
pituitary necrosis had been reported in the literature. 
Those patients with postpartum hemmrrhage comprised the 
largest group and had the most severe degree of necrosis; 
in only four cases unassociated with pregnancy was necrosis 
widespread. He concluded that necrosis of the anterior 

-2- 
pituitary was a relatively frequent finding in females dying 
in the puerperium, that necrosis began at about the time of 
delivery, and that it was due to thrombosis rather than 
3 
embolus, that is, that it was not a secondary event. 
Although Sheehan was the first physician to attribute 
anterior pituitary necrosis to the concurrent obstetrical 
accident, the first observer to report a case of acute 
extensive necrosis of the anterior pituitary in a patient with 
a severe obstetrical hemorrhage was the Polish pathologist, 
Glinski, in 1913. He described the case of a 37 year old 
female who suffered severe uterine bleeding secondary to 
uterine atony at the time of delivery. A Caesarean section 
was performed and nine days later the patient succumbed to 
puerperal sepsis. On post mortem examination, extensive 
pituitary necrosis was found. Glinski concluded that the 
necrosis was the cause and not the result of the uterine 
atony, hemorrhage, and collapse in women at the time of 
delivery. Had he reasoned differently, this clinical 
4 
entity might have been named Glinski* s Syndrome. 
Sheehan stressed that anterior pituitary necrosis 
secondary to postpartum hemorrhage was not a rare occurrence. 
Upon examination of the pituitaries of 127 patients who 
had died 12 hours to 35 days postpartum, he discovered 
22 large and 19 small or medium-sized cases of pituitary 
5 
necrosis. He observed that anterior hypopituitarism. 
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which is most commonly secondary to postpartum hemorrhage , 
was not rare in the general population. In 1939, he 
estimated that there were two severe cases and seven less 
severe cases per ten thousand people and that these cases 
often went unrecognized^. Sheehan and Summers noted that 
among 95 cases of histologically proven chronic hypopituitar- 
g 
ism, 62 cases were related to postpartum hemorrhage . In a 
survey of 128 females who sustained hemorrhage and collapse 
at the time of delivery, 41(32%>)' showed some degree of 
. . . . . . 9 
diminished pituitary function . 
There is no general agreement about the pathogenesis 
of Sheehan’s Syndrome. The special vulnerability to 
ischemia of the pituitary gland during pregnancy is probably 
related to the two to three-fold increase in size of the 
adenohypophysis during pregnancy^, as it is rare for 
reduced blood flow to cause pituitary necrosis in the non¬ 
pregnant female^. Indeed, reversible physiologic bitemporal 
hemianopsia can occur secondary to pituitary enlargement 
) 
12 
during pregnancy . Sheehan contends that necrosis is 
produced by local ischemia due to vasospasm in the arterial 
supply. This results from any severe circulatory collapse 
at the time of delivery, most commonly due to obstetrical 
1 3 
hemorrhage . Sheehan and Standfield propose that during 
pregnanacy the vascular system of the pituitary becomes 
especially sensitive to vasoconstrictive stimuli and that 

pregnancy therefore predisposes to pituitary necrosis. 
However, Kopaniky and Cann have found in dogs that pituitary 
vasculature responds guite differently to hypoperfusion. 
Using a miniature thermoelectric probe to continuously 
record blood flow in the anterior pituitary in the anesthetized 
dog, they have demonstrated that as hemorrhage increases, 
pituitary blood flow falls initially but then increases to 
rates greater than control. "Since cerebral blood flow in 
the dog is maintained but not significantly increased 
following hemorrhage, it appears that the rise above control 
level in the anterior pituitary is not secondary to maintenance 
of blood flow to the cerebral vascular tree. Instead, this 
change appears to be localized to the hypothalamo-hypophysial 
14 
vasculature. Gottshalk and Tilden have emphasized the 
importance of the physiologic increase in pituitary size* 
during pregnancy and have noted that a massively enlarged 
gland confined within a limited space (the rigid sella 
turcica) would be exposed to considerable pressure and 
would suffer some degree of vascular compression. In this 
setting, a sudden drop in blood pressure due to postpartum 
hemorrhage would allow the increased tissue pressure to 
cause collapse of the pituitary vasculature and ischemic 
.15 . . 
necrosis . Consistent with this hypothesis, the patient 
Gottshalk and Tilden describe in their article was found on 
autopsy to have a segment of the anterior lobe of the 
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pituitary protruding from the sella and no necrosis was 
found in this area. The importance of the role of the sella 
in confining the enlarged pituitary gland of pregnancy has 
received further emphasis from the studies of Meador and 
Worrell. By using lateral sella turcica area measurements 
of skull reontgenograms, they have found that the sella 
turcica in 10 of 14 (71/6) patients with Sheehan’s Syndrome 
was significantly smaller (P less than .001) than it was 
in normal controls. They suggest two possible explanations 
for the small sella in patients with Sheehan's Syndrome: 
either the pituitary fossa decreases in size after the necrosis 
and atrophy of the gland, or the sella turcica is already 
small at the time of obstetrical hemorrhage. The postulate 
of a decrease in gland size causing a decrease in pituitary 
fossa size is guestionable as small lateral fossa areas were 
detected in their patients as early as eleven months after 
the postpartum hemorrhage, presumably too early for such 
shrinkage to occur. However, if the sella is already small 
at the time of hemorrhage, this would further augment the 
pressure on the pituitary and this abnormality in configuration 
of the sella would predispose a bleeding patient to pituitary 
• 16 
necrosis 
A classical case of Sheehan's Syndrome presents as complete 
anterior hypopituitarism. In 1938, Sheehan and Murdoch found 
that their patients with Sheehan's Syndrome characteristically 




sometimes change in weight." Murdoch, in 1962, 
presented his clinical findings in 57 patients with Sheehan’s 
Syndrome. 44 had total amenorrhea since the obstetrical 
accident, 9 had oligomenorrhea, 3 gave no information about 
their menstrual status, and 1 had regular menses. 41 had 
cold intolerance. 51 had obvious pallor. 56 had loss of 
body hair and of pubic, axillary, and eyebrow hair. 9 of 9 
patients examined had genital atrophy. 23 patients complained 
1 8 * 
of slow or monotonous speech. Other signs and symptoms of 
Sheehan’s Syndrome are failure of lactation postpartum, 
infertility, breast atrophy and decreased pigmentation of 
the areolae, increasing fatigue and lethargy, deep hoarse 
voice, thick: coarse or waxy skin, macroglossia, decreased 
libido, and chronic constipation. Although severe pituitary 
necrosis usually causes total loss of anterior pituitary 
function, isolated or partial deficiencies of pituitary 
19 
hormones may occur , and there is no definite sequence of 
. 20 
loss of hormone function . There have been numerous 
reports of patients with Sheehan’s Syndrome having normal 
, , . . 21-28 
pregnancies and deliveries 
Sheehan's Syndrome does not develop within a predictable 
period of time after the obstetrical accident. It often 
emerges insidiously and exposes the patient to considerable 
• 29 30 
risk ' . Sheehan admonishes that endocrine changes should 
be carefully evaluated in every case where obstetrical 
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circumstances suggest that pituitary necrosis may have occurred 
Although a minimum blood loss of 500 cc. at the time of 
delivery and shortly thereafter is probably necessary to 
32 
cause Sheehan’s Syndrome , There is no correlation between 
the amount of postpartum hemorrhage and the likelihood of 
. . 33 
developing pituitary insufficiency . Therefore, it is 
possible that apparently normal woemn with minimal postpartum 
blood loss may have impaired anterior pituitary function. As 
Sheehan’s Syndrome is readily amenable to successful treatment 
with hormonal replacement therapy, it would be useful to 
know the incidence among asymptomatic patients at risk of 
laboratory evidence of anterior pituitary insufficiency and 






A. Patient Selection 
All patients at Yale New Haven Hospital with a discharge 
diagnosis of postpartum hemorrhage within the past ten years 
were identified through chart review of Yale New Haven Hospital 
records. Postpartum hemorrhage was defined in this study as 
. 34 
a minimum estimated blood loss of 500 cc. . One hundred forty 
patients were identified. Patients were grouped according 
to the responsible obstetrician at the time of their postpartum 
hemorrhage. Those obstetricians (7) with the largest number 
of patients (80) were contacted and the study was discussed 
with them. After obtaining the obstetricians* consents, 
38 of the 80 patients could be located; each received a 
description of the project and their participation was 
solicited. Patients in this group of 38 who were pregnant, 
breast-feeding, on drug therapy other than estrogen-progesterone 
compounds, taking medication which would interfere with 
laboratory determination of hormone levels, or who had a history 
of hypertension or diabetes mellitus were excluded from the 
study (4). Twelve patients from the initial group of 38 
agreed to participate. Three of these patients were taking 
estrogens: Orthonovum 1/80 for contraception (two patients), 
and Premarin 1.25 mg. daily for three weeks of each month 
(one patient who was status post bilateral salpingo-oophorect- 
omy and hysterectomy for pelvic actinomycosis). A thirteenth 
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patient, a research technician at the Yale New Haven 
Hospital, volunteered to participate, met the criteria for 
inclusion in the study, and was accepted. Patients were not 
selected according to age, parity, obstetrical or medical 
history, amount of estimated blood loss in excess of 500 cc., 
duration of hemorrhage, presence of hypotension or shock;, 
interval between delivery and time of hemorrhage, or obstetrical 
cause of hemorrhage. The nature of the study was discussed 
in detail with each patient and ail subjects gave written 
informed consent. 
B. Protocol 
All patients arrived at 8 AM after an overnight fast 
and were interviewed and examined. Formal fields of vision 
examination was obtained using the Goldmann perimeter. All 
patients had sella turcica x-rays, twenty-four hour urine 
collections for 17-hydroxycorticosteroids, 17-ketosteroids, 
and creatinine, 8 AM and 8 PM serum cortisols, unstimulated 
8 AM serum FSH and LH samples, and fasting thyroid function 
tests. Each patient then underwent an insulin tolerance 
test as follows: with a constant intravenous infusion of 
normal saline through an indwelling scalp vein needle 
placed in the antecubital fossa, a bolus of regular insulin 
0.1 units/kg body weight was injected over 30 seconds at 
time 0. Serum samples were obtained at -30,0, 30,45,60,90, 
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and 120 minutes for glucose, cortisol, growth hormone (GH), 
prolactin (PRL), and thyrotropin (TSH) determination. Patients 
were carefully monitored for hypoglycemic reactions which 
consisted of lightheadedness, fatigue, warmth, hunger, 
sweating, and drowsiness. Vital signs were taken frequently 
throughout the test. Concentrated intravenous glucose 
solution was available but not required. The test was 
terminated at 90 minutes for one patient (patient 3) as 
serum could not be successfully obtained thereafter. Two 
patients (patients 1 and 2) required an insulin dose of 0.15 
units/kg body weight in order to acheive significant 
hypoglycemia (defined as a fall in blood glucose of greater 
than 50% from baseling to below 40 mg/100 ml and hypoglycemic 
symptomatology). All patients received ample glucose 
repletion upon completion of the test and left the hospital 
only after a stabilization of vital signs for one hour. On 
the following day, a thyrotropin-releasing-hormone (TRH) 
stimulation test for evaluation of TSH and PRL response was 
performed as follows: with a constant intravenous infusion 
of normal saline through an indwelling scalp vein needle 
placed in the antecubital fossa, a bolus of 100 micrograms 
of TRH was injected over 30 seconds at time 0. Serum samples 
were obtained at -15,0,15,30,45,60,90, and 120 minutes for 
TSH and PRL determination. Some patients transiently 
experienced nausea, facial flushing, urinary urgency, or a 
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metal lie taste at the time of TRH injection; there were 
no other adverse reactions. 
Additionally, one patient (patient 7) required a 
metapyrone test and an ACTH stimulation test. Metapyrone at 
a dose of 750 mgs. orally every four hours was given for 
twenty-four hours; twenty-four hour urines for 17-hydroxy- 
corticosteroids, 17-ketosteroids, compound S, and creatinine 
were obtained the day before, the day of, and the day after 
metapyrone administration. Vital signs were carefully 
■monitored. Two days later, the patient received an ACTH 
. . . R 
stimulation test as follows: intravenous Cortrosyn 
0.5 mgs. in 0.5 liters of a five % dextrose-water solution 
was infused at a constant rate over eight hours from 9 AM 
and 5 PM. Beginning at 8 AM, a twenty-four hour urine 
collection for 17-hydroxycorticosteroids, 17-ketosteroids, 
compound S, and creatinine was obtained. Serum cortisol 
levels were obtained at 8 AM, 2 PM, 4 PM, and 6 PM. The 
patient experienced no adverse effects. 
This protocol was approved by the Human Investigation 
Committee of the Yale New Haven Hospital. 
C. Assays 
Radioimmunoassay determinations of serum levels of 
GH, PRL, and TSH were performed by Dr. Richard K. Donabedian. 
Burroughs-Welcome, Inc. provided the antisera for the GH 
assays, the National INstitute of Health provided antisera 
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for the PRL assays, and Cal-Biochem, Inc. provided antisera 
for the TSH assays. Serum cortisol determinations were 
performed by the Yale New Haven Hospital Department of 
Clinical Chemistry according to the fluorimetric method of 
35 
DeMoor . 17-hydroxycorticosteroids were determined spectro- 
photometrically by the Yale New Haven Hospital Department of 
Clinical Chemistry according to the metho described in 
Standard Methods of Clinical Chemistry, vol. 4, Academic 
Press, 1963. 17-ketosteroids and compound S were determined 
spectrophotometrically by the Yale New Haven Hospital 
Department oc Clinical Chemistry according to a modification 
3 6 
of the method of James . Serum thyroxine and thyroid-binding 
37 
capacity were determined by the method of Seligson 
D. Statistics 





The present age, date of postpartum hemorrhage, estimated 
blood loss (EBL), transfusions of units of whole blood 
received, interval between delivery and postpartum hemorrhage, 
cause of hemorrhage, and degree of hypotension are presented 
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All patients with the exception of patient 7 had 
unremarkable medical histories and physical examinations. 
Patient 7 had idiopathic galactorrhea. Patients 5 and 12 
had been receiving Orthonovum 1/80 for oral contraception 
for one and one half years and twelve years, respectively. 
Patient 1 underwent a bilateral salpingo-oophorectomy and 
hysterectomy for pelvic actinomycosis in 1971 and since 
then had been receiving Premarin 1.25 mg. orally each day 
for the first three weeks of each month. All patients had 
normal x-ray evaluation of the sella turcica and normal 
fields of vision as determined by Goldmann perimetry. The 
results of 8 AM and 8 PM serum cortisol levels, thyroid 
function tests, and 24 hour urinary 17-hydroxycorticosteroids, 
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The elevated levels of serum cortisol in patients 5 and 12 
and of thyroxine and thyroid binding capacity in patients 
1,5, and 12 are ascribed to the effect of their estrogen- 
38 39 
containing medications * . The abnormally high 8 PM 
cortisol of patient 3 is attributed to her great anxiety and 
near hysterical syncopal espisode at the time of venipuncture. 
The low level of 17-hydroxycorticosteroid production by 
patient 7 was further investigated as described below (p 25). 
Table III (p 19) indicates each patient's unstimulated 
serum FSH and LH values, the date of the menstrual cycle at 
the time of sampling, and the use of estrogen-containing 
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An insulin tolerance test was done in all patients 
and determinations made for glucose, cortisol, GH,PRL, 
and TSH and a TRH stimulation test was also done in all 
patients and PRL and TSH levels were determined. All 
patients developed hypoglycemia with a fall in glucose 
to less than 40 mgs per dl. and associated sweating. 
Two patients, patients 1 and 2, reguired regular insulin 
0.15 units per kg body weight in order to achieve significant 
hypoglycemia. 
Although it has been reported that the TRH stimulation 
test for TSH and PRL and the insulin tolerance test for 
GH, PRL, and cortisol can be performed simultaneously 
without modification of the hormonal responses to either 
. 40 
TRH or insulin , it was decided to perform each test 
on a separate day. Besser et. al. state that there is no 
evidence for competition between pituitary mechanisms 
involved in GH and TSH secretion in man in response to 
41 
simultaneous TRH and msulm-hypoglycemia stimulation 
However, Guansing et. al. have observed a statistically 
significant rise in TSH to hypoglycemia in patients with 
. . . 42 
pituitary disease while there is no TSH response in 
, 43 44 
normal patients ’ . Therefore, the two tests were 
performed on separate days to avoid the possible uncertainty 
of whether a marked TSH response in a patient with pituitary 
disease who received insulin and TRH simultaneously was due 
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solely to hypoglycemia, therefore indicating no response to 
TRH, or whether the TSH rise was due to TRH alone or to a 
combination of both stimuli. A TSH response to insulin, 
45 
observed only in patients wtih pituitary disease , could 
therefore be clearly separated from a TSH response to TRH. 
Additional reasons to perform the tests on different days 
were: 1) a large increase in serum levels of GH may inhibit 
46 
TRH stimulation of TSH , and 2) cortisol modulates TSH 
levels and may do so by diminishing the TSH response to 
TRH 47»48. 
Individual patient responses for the TSH stimulation 
test and the insulin tolerance test appear in Appendix I 
(pp 54-60) with calculations of the mean, the standard error of 
the mean (SEM), and the standard deviation (SD). Results are also 
grouped according to whether or not the patient was receiving 
estrogen; three patients (patients 1,5, and 12) were receiving 
estrogens, ten patients were not. Means, SEMs, and SDs are 
indicated for each group. Results for each test are presented 
in two figures. The first figure shows the baseline and peak 
response of all thirteen patients as well as the mean and 
SEM for all thirtenn patients and the grand mean ( a 
pooling of mean and SEM values derived from a series 
of normal control groups presented in the literature), 
the standard error of the grand mean, and the 95 per cent 
confidence limits derived from normal control values 
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reported in the literature. The second figure compares the 
means and SEMs for all thirteen patients, for the three 
patients receiving estrogens, the ten patients not receiving 
estrogens, and the grand mean, the standard error of the 
grand mean, and two standard deviations of a single 
observation of the grand mean which defines a 95/6 confidence 
range. These confidence limits are derived from the literature 
and although they approximate a true definition of the 
range of normal values, they cannot be precisely statistically 
compared to the results obtained in this study. The 
relative newness of TRH as a diagnostic agent and of the 
radioimmunoassays for pituitary hormones, the great 
variation in methodology, technique, and standardization 
of these radioimmunoassays, the difference in methods 
of clinical testing among clinical researchers, and the 
differences in statistical analysis and presentation are 
all potential sources for discrepant results. Explanations 
of the selection of normal control groups from the literature 
as well as statistical methods used to determine the 
grand mean, standard error of the grand mean, and 
standard deviation of a single observation are presented 
in Appendix II (pp 61-65). 
Cortisol response to insulin hypoglycemia 
The results of cortisol response to hypoglycemia are presented 
in Figure l(p29) and Figure 2 (p3Q). One patient (patient 7) had an 
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inadequate response and three patients (patients 1,5, and 
12) had a heightened response. The patient with the inadequate 
cortisol response underwent further evaluation of 
her pituitary-adrenal axis as described below (p 25). 
In comparison to the 95% confidence limits, all patients 
not receiving estrogen fell approximately within these 
limits. The three patients receiving estrogen as indicated 
in Figure 1 (p 29)(patients 1,5,and 12) all have peak values 
far outside of the confidence limits. As indicated in Figure 2 
(p 30), there is a marked difference between the mean peak 
values for those patients not receiving estrogen and those 
patients receiving estrogen. Comparison of these values by 
a paired MtM test showed that the difference was significant 
with P less than .0001. The elevated baseline values of 
patients 5 and 12 are attributable to the effect of estrogen 
49 
on serum cortisol 
Growth hormone response to insulin hypoglycemia 
The results of GH response to hypoglycemia are presented 
in Figure 3(p 31) and Figure 4(p 32). All patients responded with 
an increase in GH although the response of patient 2 was modest. 
The breadth of the 95% confidence limits for this test 
is such that it is not useful to discriminate between normal 
and abnormal responses. As shown in Figure 4 (p 32), the 
mean peak responses of patients receiving estrogen and 
not receiving estrogen were comparable and were not 
significantly different. As a single group of thirteen 
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patients, the mean peak response was adequate and 
compared favorably to that derived from the literature. 
Prolactin response to insulin hypoglycemia 
The results of the PRL responses to hypoglycemia are presented 
in Figure 5 (p33) and Figure 6(p34). Nine patients had 
adequate PRL responses while patients 7,8,9, and 13 showed 
minimal increases in PRL. However, this second group of 
four patients did show an adequate PRL response to TRH 
stimulation. Unfortunately, no 95% confidence limits could 
be derived from the literature. Figure 6(p34) indicates that 
the mean peak responses of the group receiving estrogen and the 
group not receiving estrogen were different; however, this 
difference was not significant. As a single group of 
thirteen patients, the mean peak PRL response was adequate 
and compared favorably to that derived from the literature. 
Prolactin response to TRH 
The results of the PRL responses to TRH are presented in 
Figure 7(p35) and Figure 8(p36). All patients responded with 
an increase in PRL and all were approximately within the 
95% confidence limits. As shown in Figure 8(p36), the difference 
between the mean peak of the patients receiving estrogen and 
not receiving estrogen was insignificant. As a single group 
of thirteen patients, the mean peak PRL response was adequate 
although lower than that of the mean peak PRL responses 
derived from the literature. However, the mean 
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PRL increments derived from the literature and from 
this study, 19.3 ng/ml and 17.3 ng/ml, respectively, are 
quite comparable. 
Thyrotropin response to TRH 
The results of the TSH response to TRH are presented in 
Figure 9(p37) and Figure I0(p38). All patients responded with 
an increase in TSH and all were approximately within the 
95/6 confidence limits. As shown in Figure I0(p38), 
there was no apparent effect of estrogen. As a single group 
of thirteen patients, the mean response was adequate and 
almost identical to that derived from the literature. 
Thyrotropin response to insulin hypoglycemia 
The TSH response to hypoglycemia is presented in Figure 11 
(p39) and Figure 12(p40). The majority of the patients 
(a total of 8) had no detectable levels of TSH at any time during 
the test. Minimal TSH responses were observed among those 
patients with detectable levels of TSH and there was only 
insignificant fluctuation in these values during the test. This 
is comparable to the insignificant response of TSH to insulin 
hypoglycemia reported in the literature ^'^and used for 
supplying a normal control group. Estrogen had no effect 
on TSH response as seen in Figure 12(p40). 
One patient, patient 7, failed to manifest a rise in 
cortisol to adequate insulin hypoglycemia. Additionally, 
she had a subnormal 24 hour production of 17-hydroxycortico- 
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steroids. She therefore underwent a metapyrone test and 
an ACTH stimulation test as described above. Baseline 
urinary steroids were obtained eight days before and two 
days after the testing period. The results are presented 
in Table IV(p27). 
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The results presented in Table IV indicate that patient 
7 has a normal pituitary response to metapyrone and a normal 
adrenal response to ACTH stimulation. These tests are not 
confirmatory for pituitary disease. 

-29- 




all 13 normal 
patients patients in 
in study, literature, 












































































































































































FIGURE 8. PROLACTIN RESPONSE TO TRH 

























FIGURE 9._THYROTROPIN RESPONSE TO TRH 
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Sheehan's Syndrome is the major cause of anterior 
. . 52 
pituitary insufficiency . As there is no correlation between 
the amount of blood loss and the development of pituitary 
. . 53 
insufficiency , it is possible that apparently normal 
women with minimal blood loss may have impaired pituitary 
function. Anterior pituitary function was evaluated in 
thirteen patients. This study failed to demonstrate any 
evidence of pituitary disease in this patient population 
at the present time. (This does not mean that 
54 
hypopituitarism may not develop in the future .) It seems 
probable that subclinical defects in asymptomatic patients 
at risk for Sheehan’s Syndrome are uncommon. Perhaps 
pituitary disease does not exist in the absence of clinical 
symptoms or perhaps the subclinical state of hypopituitarism 
is too subtle to be detected with the present level of 
sophistication of endocrine testing. Nevertheless, because 
mild instances of Sheehan's Syndrome are often overlooked and 
the diagnosis considered progressively less often as the date 
of postpartum hemorrhage becomes more remote, all survivors 
of this obstetrical complication, however small the guantity 
55 
of hemorrhage, should be continually observed . It may be 
argued that the degree of blood loss in this patient group 
was too small to cause pituitary damage. However, Effkemann 
and Muller-Jager found that in a group of 84 patients who 
lost between 800 and 1600 cc. of blood at the time of 
delivery, sixty per cent of the twenty patients who lost 
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bet ween 1200 and 1600 cc of blood suffered decreased 
menstrual function and fifty per cent of these twenty 
women became permanently sterile^6. 
The endocrine status of patient 7 must be clarified 
in order to conclude that there was no evidence of pituitary 
disease among these thirteen patients. Although this patient 
failed to manifest a rise in cortisol in response to insulin 
hypoglycemia, further testing revealed a normal response of 
the pituitary to metapyrone, indicating normal ACTH 
stimulation. Confirmation of adeguate adrenal response 
to stimulation was obtained by a satisfactory ACTH test. 
As all of patient 7's other pituitary hormones responded 
adeguately to stimulation, there was no evidence of 
pituitary disease. Failure of insulin hypoglycemia to produce 
a rise in cortisol is not inconsistent with a normal 
pituitary response to metapyrone. Indeed, the results of 
these two tests may be helpful in localizing this patient*s 
endocrine defect to her hypothalamus. Hypoglycemia very 
likely acts at the hypothalamic level^ ^ to stimulate 
corticotropin-releasing-factor (CRF ) ^ which in turn 
stimulates ACTH secretion which causes cortisol release. 
62 
Metapyrone acts by blocking the synthesis of cortisol 
which acts in a negative feedback fashion to inhibit ACTH 
and probably CRF. (It is not clear whether cortisol is 
inhibitory ar the level of the pituitary or the hypothalamus 




loci of action . However, Upton et. al. believe that 
there is strong evidence that CRF is regulated solely by 
ACTH and therefore that cortisol would inhibit ACTH at the 
. 64 
pituitary level only .) Metapyrone, by lowering cortisol 
levels, would therefore stimulate the pituitary and perhaps 
the hypothalamus as well to increase cortisol synthesis 
and release while hypoglycemia would stimulate only the 
hypothalamus. Thus a negative cortisol response to hypoglycemia 
coupled with a normal metapyrone response might indicate 
normal pituitary function but abnormal hypothalamic function. 
One might then hypothesize that a hypothalamic defect in the 
S 5 
production of CRF, which largely controls ACTH secretion" , 
might lead to a lower "turn-off" point for the ACTH-cortisol 
"thermostat" which would be reflected by lower levels of 
cortisol metabolites such as 17-hydroxycorticosteroids. 
Such a hypothesis might satisfactorily explain the low levels 
of 17-hydroxycorticosteroids observed twice in patient 7 
(less than 1 and 2.3 mg/ total volume) and relate this abnormality 
to the absent cortisol response to hypoglycemia and the 
normal response to metapyrone. The patient*s galactorrhea 
may also be due to hypothalamic disease; certainly there was 
no evidence for a pituitary casue of galactorrhea. Furthermore, 
since it seems likely that TRH acts at the pituitary to 
release PRL in man ’ ° , and since it is known that hypoglycemia 
acts on the hypothalamus to stimulate PRL^ "^1, this patientas 




despite a normal PRL response to TRH may be a further 
indication of adequate pituitary function and hypothalamic 
disease. 
Several interesting aspects of the nature of tests of 
endocrine function were apparent in this study. It is evident that 
a blood glucose level of less than 40 mg/dl. must be obtained 
before a patient can be assumed to have pituitary dysfunction on 
the basis of an abnormal insulin tolerance test. The variability 
of individual response to the ’‘standard*’ initial dose of regular 
insulin 0.1 units/kg body weight makes it necessary to employ a 
larger dose of insulin before diagnosing pituitary insufficiency. 
Landon et. al. have demonstrated that there was no cortisol 
response to insulin hypoglycemia in normal patients in whom the 
blood sugar did not fall below 40 mg/dl. . Glick has shown that 
in normal patients the hypoglycemic threshold for GH release is 
a fall in blood glucose of between 20 and 30 mg/dl. unassociated 
. . . . . 73 
with the subjective manifestations of stress . Greenwood et.al. 
have studied the effect of varying the dose of regular insulin 
from 0.025 to 0.15 units per kg. body weight and found that thec 
responses of GH and cortisol were directly proportional to 
74 
the dose of insulin administered . While Cohen and Gala 
failed to demonstrate a rise in PRL in response to a mean 
75 
fall in blood glucose to 25 mg/dl. , Wilson et. al. found 
that at a hypoglycemic level of 25 mg/dl. obtained by constant 
infusion of regular insulin 0.04 units/kg body weight/hour there 
was no significant PRL response; however, with the use of regular 
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insulin 0.2 units/kg body weight as a bolus a mean glucose 
level of 9 mg/dl. was obtained and the mean PRL response 
was guite high 
76 
Similarly, Noel et.al., using regular 
insulin 0.2 units/kg body weight, obtained a mean glucose 
77 
level of 15 mg/dl which caused a striking rise in PRL 
Two patients in this study required an insulin dose of 
0.15 units rather than 0.1 units. Patient 1 had no response 
to 0.1 units and clearly required a larger dose. However, 
patient 2 responded to a dose of 0.1 units with a fall in 
glucose from 87 to 42 mg/dl., a fall of 52% from baseline, 
and experienced sweating, hunger, lightheadedness, 
drowsiness, and modest changes in pulse and blood pressure. 
Nevertheless, the patient had no cortisol, GH, or PRL 
response. If an adequate and diagnostic insulin tolerance 
test had been defined as a fall inglucose of 50% and associated 
symptomatology, then this patient would have been considered 
abnormal. A second test was performed, this time with 0.15 
units, and the glucose fell 76% to 20 mg/dl.; adequate 
cortisol and PRL responses were obtained but the GH response 
remained modest. The duration of maximal hypoglycemia 
may also correlate with the height of the hormonal response; 
Patient 1 had sustained maximal hypoglycemia and responded with 
marked secretion of all hormones. As it is apparent that 
the hormonal response correlates with the degree of 
hypoglycemia, it would be useful to present the results of 
the insulin tolerance test as a ratio of the change in each 
A hormone 




Such a ratio would define the slope of a straight line as 
indicated in Figure 13(p47). Figure I4(p48) is an attempt to 
apply this suggestion to the cortisol results obtained in this 
study. The ten patients not taking estrogen are represented 
in this figure along with the mean and SEM for this group. 
The three patients receiving estrogen are not included here 
because the effect of estrogen on cortisol response (p 23) 
precludes comparison with patients not taking estrogen. 
It can be seen that with the exception of patient 7, who did 
not respond to insulin hypoglycemia and therefore can be 
excluded from consideration, these patients' responses fall quite 
close to the mean ± SEM. This method of reporting the results 
of insulin tolerance tests would allow patients with varying 
degrees of hypoglycemia to be compared and would also provide 
a useful definition and range of normal responses of each 
hormone to hypoglycemia. However, it may be necessary to 
take into account the duration of maximal hypoglycemia in 
order to more clearly unify data. It would be useful to evaluate 
the results of hormonal responses to hypoglycemia in a large 
population of normal age and sex-matched controls and to 
present those results in the manner described above. 
In their study of PRL responses to insulin hypoglycemia, 
Cohen and Gala conclude that "insulin hypoglycemia is not a 
useful diagnostic test for prolactin secretion and cannot be 
used as such for assessment of pituitary reserve." and that 
the"use of insulin hypoglycemia as a diagnostic aid for 
7 8 
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Using regular insulin 0.1 units/kg body weight in three 
normal mean and two normal women, they obtained a mean blood • 
glucsoe level of 25 mg/dl. but did not observe any increase 
in PRL levels. Further, two patients who received the same 
insulin dose had significant PRL rises either before the glucose 
nadir was achieved or in absence of adequate hypoglycemia. 
If the differences in the two PRL radioimmunoassays can be 
disregarded, the results for their five patients, who had a 
mean level of hypoglycemia almost identical to that of the 
present study, are quite discrepant with those of the present 
study and of Copinschi et. al., who showed a significant PRL 
79 
response in sixteen patients to a mean hypoglycemia of 28 mg/dl. 
Although four of the thirteen patients in the present study 
failed to increase PRL levels in response to hypoglycemia, the 
other nine patients had significant PRL responses and the mean peak 
PRL for the entire group was 27.4 ng/ml. with a mean peak 
increment of 18.4 ng/ml. and a mean peak percentage increment 
compared with baseline of 214%. It is possible that the five 
patients reported by Cohen and Gala had other evidence of 
hypothalamic-pituitary dysfunction and were therefore not 
normal patients. It would have been useful to perform a TRH 
stimulation test for PRL in this group of five patients to 
see if hypoglycemia was ineffective in stimulating PRL in 
otherwise normal patients or if these patients had abnormalities 
as might have been shown by the TRH test. Phenothiazine 
80 
stimulation of PRL would also give important information 
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It is difficult to explain the anomalous responses of the 
two patients in Cohen and Gala's study who had substantial 
PRL secretion but not in response to hypoglycemia; no 
similar occurrence was observed in the present study. 
Although Cohen and Gala agree with the results of Wilson 
Ol P O 
et. al. and Noel et. al. who showed that significant 
PRL responses could be obtained consistently when the blood 
glucose level was decreased to 9 mg/dl. and 15 mg/dl. 
respectively, they maintain that this degree of hypoglycemia 
is too extreme to make insulin hypoglycemia a safe and 
practical test of PRL secretion. Nevertheless, the results 
8 3 
of the present study and of Copinschi et. al. indicate 
that a decrease in the blood glucose to the relatively safe 
level of 25 mg/dl. is quite effective in stimulating PRL and 
it appears that insulin hypoglycemia is a valuable tool in 
the evaluation of PRL secretion. 
As both TRH stimulation and insulin tolerance tests 
were performed on all thirteen patients, it is possible to 
compare the usefulness of both tests in evaluating PRL 
secretion. As presented in Figure 7 (p35), all patients 
had adequate PRL responses to TRH. As shown in Figure 5(p33), 
nine of thirteen patients had adequate PRL responses to hypo¬ 
glycemia. The mean PRL baselines for all thirteen patients 
were 9.7 ng/ml. in the TRH test and 9.0 ng/ml in the insulin 
tolerance test; the mean PRL peaks for all thirteen patients 
were 27 ng/ml in the TRH test and 27.4 ng/ml. in the insulin 
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tolerance test. It therefore appears that both tests are 
useful in evaluating PRL secretion and that on the average, 
they yield remarkably similar results. However, not all 
patients responded to hypoglycemia and therefore it may be 
prudent to perform both tests. Furthermore, if, as discussed 
above (p 43), it can be shown tie t TRH affects PRL secretion 
solely at the pituitary level, performing both tests may allow 
localization of defects in PRL secretion to the pituitary 
or the hypothalamus. It would be useful to know how these 
two methods of PRL stimulation compare to a third method, 
. 84 
phenothiazine stimulation 
The failure to observe a TSH response to hypoglycemia 
in any of the thirteen patients in this study is consistent 
. t . 85 , . 86 
with the reports of Guansing et. al. and Copmschi et. al. 
that normal patients have no TSH response to hypoglycemia. 
Elevated TSH levels are found only in patients with pituitary 
87 
disease . It would be of interest to know whether 
dopamine plays a role in the inhibition of TSH response to 
hypoglycemia.,It is known that dopamine blocks TRH stimulation 
8 8 
of TSH . If pimozide, an effective dopaminergic blocking 
89 .... 
agent , could prevent the inhibition of TSH response to 
hypoglycemia, this would support a dopaminergic role in the 
failure of TSH response. 
The effect of estrogen-containing compounds on the outcome 
of these hormonal stimulation tests was insignificant except 
in the case of hypoglycemic stimulation of cortisol. The 
' 
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failure of estrogen to augment the TSH response to TRH is 
. . 90 
m conflict with the report of Ramey et.al. that oral 
contraceptives in normal euthyroid females caused a 
significant increase in TSH response to TRH. As Ramey 
presents only mean values, it is possible that there were 
a small number of patients among his group of fourteen who 
had responses that were significantly below the mean 
response and were comparable to those of the three patients 
in the present study. Thus, it may be that the failure of 
estrogen to affect the mean TSH response to TRH in the present 
study may be due to the small number of women receiving 
estrogen. Indeed, one of the three women did have a response 
significantly above the mean for all 13 patients (patient 5) 
as well as the highest response in the study. Although it is 
known that estrogen causes increased PRL response to perphenazine 
. . . 91 
stimulation m both men and women , and that the PRL response 
... .92 
to TRH is significantly higher in females than m males , 
the effect of estrogens on PRL response to TRH in normal 
females has not bee assessed. In the present study, the 
effect of estrogen on PRL response to TRH was not significant. 
Estrogen had no significant effect on the response of GH in 
this study. There are no reports in the literature on the 
effect of estrogens on the GH response to hypoglycemia. 
Merimee and Fineberg have shown that when the fall in glucose 
exceeds 40 mg/dl., there is no significant variation within 
the phases of the menstrual cycle of GH response to hypoglycemia, 
indicating the negligible effect of physiologic increases of 
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estrogen. The effect of estrogen on hypoglycemic stimulation 
of cortisol was significant with a mean peak for patients 
receiving estrogen of 58.0 micrograms/ml. in contrast to a 
mean peak of 30.1 micrograms/ml. for those patients not 
receiving estrogen (P less than .0001-paired Mt" test). 
Although it is known that pretreatment with diethylstilbestrol 
in normal children gives significantly higher peak cortisol 
93 
responses to hypoglycemic stimulation , and that oral 
contraceptives augment the peak 17-hydroxycorticosteroid 
94 
response to Piroraen stimulation , a substance which stimulates 
. . 95-97 
pituitary release of ACTH , there is no report in the 
literature of the effect of oral contraceptives on cortisol 
response to insulin hypoglycemia. No significant effect of 
estrogen on PRL and TSH responses to hypoglycemia was found 
and there are no reports in the literature on the effect of 




TRH test for TSH(microunits/ml) 
time -15 0 . 15 30 45 60 90 120 
Patient 
1 0 0 6 7 7 5 1 0 
2 0 0 13 15 15 12 6 3 
3 0 0 13 21 16 15 9 7 
4 2 2 2 11 11 8 9 6 
5 1 ' 1 24 34 23 23 13 10 
6 4 7 19 32 27 20 15 10 
7 0 0 11 9 8 6 5 3 
8 0 0 7 7 3 4 2 .7 
9 0 0 10 13 9 7 5 4 
10 0 0 9 11 10 9 6 2 
11 0 0 30 26 25 22 13 12 
12 0 0 5 6 5 4 .5 2 
13 0 0 3 10 9 7 6 2 
mean .5 . 8 11.7 15.5 12.9 10.9 7.0 4.7 
SEH* . 3 .5 2.3 2.7 2.2 1.9 1.3 1.1 
2 SD* 2.4 4.0 16.6 19.2 15.6 13.8 9.2 7.8 
Patients receiving estroqen( 3) 
mean . 3 .3 11.7 15.7 11.7 10.7 4.8 4.0 
SEM* . 3 . 3 6.2 9.2 5.7 6.2 4.1 3.1 
2 SD* 1.2 1.2 21.4 31.8 19.8 21.4 14. 2 10.6 
Patients not receiving estroqen(lO) 
mean .6 .9 11.7 15.5 13.3 11.0 . 7.6 4.7 
SEM* .4 .7 2.6 2.6 2.4 1.9 1.2 1.3 
2 SD* 2.6 4.4 16.2 16.4 15.2 12.2 7.8 8.0 







-15 0 15 30 45 60 90 120 
1 14 12 30 26 20 15 17 12 
2 8 7 20 19 19 13 12 10 
3 17 16 52 52 51 43 29 20 
4 12 9 15 13 14 7 10 9 
5 9 6 22 18 17 13 11 8 
6 11 11 37 35 28 20 11 9 
7 13 12 28 22 20 17 25 12 
•8 7 7 10 14 15 6 8 8 
9 9 7 16 12 18 10 7 9 
10 14 14 43 50 45 33 20 20 
11 13 14 20 29 21 23 19 16 
12 5 7 12 13 15 17 8 9 
13 7 8 11 17 15 12 14 10 
mean 10.7 10.0 24.3 24.6 22.9 17.6 14.7 11.7 
SEM 1.0 .9 3.6 3.8 3.3 2.9 1.9 1.2 
2 SD 7.0 6.6 26.2 27.2 23.6 20.8 13.8 8.6 
Patients receiving estrogen (3) 
mean 9.3 8.3 21.3 19.0 17.3 15.0 12.0 9.7 
SEM 2.6 1.9 5.2 3.8 1.5 1.2 2.6 1.2 
2 SD 9.0 6.4 18.0 13.2 5.0 4.0 9.2 4.2 
Patients not receiving estrogen(10)• 
mean 11.1 10.5 25.2 22.6 24.6 18.4 17.2 12.3 
SEM 1.0 1.1 4.5 3.9 4.1 3.8 3.0 1.5 
2 SD 6.6 6.8 28.8 24.6 26.0 23.8 18.8 9.2 
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time -30 0 30 45 60 90 120 
Patient 
1 90 85 20 25 20 20 15 
2 83 82 20 34 35 38 47 
3 87 87 53 41 39 43 — 
4 86 84 20 47 55 59 64 
5 85 83 25 31 35 44 57 
6 89 84 22 35 34 39 50 
7 80 79 34 61 64 78 79 
8 87 84 21 41 36 46 56 
9 80 80 25 50 50 54 66 
10 74 74 21 41 37 55 59 
11 77 78 25 30 28 42 48 
12 92 89 35 51 54 72 67 
13 80 78 24 38 43 51 60 
mean 83.8 82.1 26.5 40.4 39.8 49.3 55.7 
SEM 1.5 1.1 2.6 2.8 3.6 4.2 4.5 
2 SD 10.8 8.2 18.8 19.8 26.0 30.0 31.4 
Patients receiving e strogen(3) 
mean 89.0 89.0 26.7 35.6 36.3 45.3 46-. 3 
SEM 2.1 2.1 4.4 7.9 9.8 15.0 15.9 
2 SD 7.2 7.2 15.2 27.2 34.0 52.0 55.6 
Patients not receiving estrogen(lO) 
mean 82.3 81.0 26.5 41.8 42.1 50.5 60.3 
SEM 1.5 1.2 3.2 2.8 3.5 3.8 3.2 
2 SD 9.8 7.8 20.4 18.0 22.0 24.0 19.4 
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Insulin tolerance test for cortisol(microqrams/ml.) 
time 
Patient 
-30 0 30 45 60 90 120 
1 8 16 16 39 47 53 60 
2 11 10 12 27 27 35 34 
3 15 19 18 26 36 34 -- 
4 16 11 9 24 36 31 26 
5 27 21 20 27 43 43 48 
6 10 8 11 26 31 23 29 
7 10 13 8 12 14 7 6 
8 13 11 10 21 31 35 32 
9 18 14 14 27 30 26 27 
10 10 10 8 17 23 24 23 
11 11 9 7 20 25 31 28 
12 27 18 30 46 50 66 43 
13 6 7 14 24 29 25 20 
mean 14 12.8 13.6 25.8 32.5 33.3 31.3 
SEM 1.8 1.2 1.8 2.4 2.8 4.1 4.0 
2 SD 13,2 9.0 12.8 17.6 20.0 29.2 28.0 
Patients receiving e stroqen(3) 
mean 20.7 18.3 22.0 37.3 46.7 54.0 50.3 
SEM 6.3 1.5 4.2 5.5 2.0 6.7 5.0 
2 SD 22.0 5.0 14.4 19.2 7.0 23.0 17.6 
Patients not receiving estroqen(lO) 
mean 12.0 11.2 11.1 22.4 28.2 27.1 25.0 
SEM 1 .1 1. 1 1.1 1.6 2.1 2.7 2.8 
2 SD 7.0 7.0 6.8 9.8 13.0 16.8 16.6 
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Insulin tolerance test for growth hormone(nq/ml.) 
time 
Patient 
-30 0 30 45 60 90 120 
1 2 1 1 45 60 70 60 
2 1 1 3 4 1 1 1 
3 1 1 1 4 28 64 -- 
4 5 12 8 8 28 52 10 
5 2 2 1 2 16 24 16 
6 1 1 1 12 40 60 64 
7 6 2 0 1 12 7 3 
8 5 2 1 4 40 40 45 
9 7 3 12 30 40 40 15 
10 10 2 1 5 20 24 12 
11 5 6 1 9 24 60 60 
12 1 1 1 44 65 40 16 
13 1 1 1 14 36 44 20 
mean 3.6 2.7 2.5 14 31.5 40.5 26.8 
SEM .8 .9 1.0 4.3 5.0 6.0 6.8 
2 SD 5.8 6.2 7.0 31.0 36.2 43.0 47.0 
Patients receivinq < estroqen(3) 
mean 1.7 1.3 1.0 30.3 47.0 44.7 30.7 
SEM . 3 .3 0 14.2 15.6 13.5 14.7 
2 SD 1.2 1.2 0 49.0 54.0 46.8 50.8 
Patients not receivinq estroqen(lO) 
mean 4.2 3.1 2.9 9.1 26.9 39.2 .25.6 
SEM 1.0 1.1 1.2 2.6 4.1 7.0 8.1 





-30 0 30 45 60 90 120 
1 
10 7 10 30 28 43 22 
2 10 11 6 11 18 20 14 
3 17 15 15 15 25 35 -- 
4 9 8 11 30 27 19 16 
5 7 8 9 23 43 36 30 
6 11 9 10 34 39 41 35 
7 12 12 12 7 11 12 14 
8 9 7 7 11 8 9 10 
9 5 5 6 9 10 10 6 
10 11 10 9 33 31 19 17 
11 13 12 12 18 38 47 45 
12 7 7 6 20 11 9 15 
13 8 9 9 7 6 10 9 
mean 9.9 9.2 9.4 19.1 22.7 23.8 19.4 
SEM .9 .8 .8 2.8 3.6 4.0 3.4 
2 SD 6.2 5.4 5.4 20.2 25.8 28.8 23.2 
Patiente receivinq estroqen(3) 
mean 8 7.3 8.3 24.3 27.3 29.3 22.3 
SEM 1.0 . 3 1.2 3.0 9.2 10.4 4.3 
2 SD 3.4 1.2 4.2 10.2 32.0 36.0 15.0 
Patients not receivinq estroqen(lO) 
mean 10.5 9.8 9.7 17.5 21.3 22.2 18.4 
SEM 1.0 .9 .9 3.4 3.9 4.4 4.3 
2 SD 6.4 5.8 5.8 21.6 24.8 27.8 26.0 
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Insulin tolerance test for thvrotropin(microunits/ml.) 
time 
Patient 
-30 0 30 45 60 90 120 
1 0 0 .8 .6 0 .4 .5 
2 0 0 0 0 0 0 0 
3 1 0 0 1 0 0 — 
4 0 0 0 0 0 0 0 
5 3 2 0 0 0 0 0 
6 8 7 4 4 3 2 2 
7 3 3 4 0 . 0 1 4 
8 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 
10 0 0 0 0 0 0 0 
11 6 4 2 1 1 1 1 
12 0 0 0 0 0 0 0 
13 0 0 0 0 0 0 0 
mean 1.6 1.2 .8 .5 .3 .3 . 6 
SEM .7 . 6 .4 .3 .2 .2 .4 
2 SD 5.4 4.4 3.0 2.2 1.8 1.2 2.4 
Patients receivinq estroqen(3) 
mean 1.0 .7 .3 . 2 0 .1 .2 
SEM 1.0 .7 .3 .2 0 .1 . 2 
2 SD 3.4 2.4 1.0 . 6 0 .4 .6 
Patients not receivinq estroqen(10). 
mean 1.8 1.4 1.0 .6 .4 .4 .4 
SEM .9 .8 .5 .4 .3 .2 .2 




Explanation of Selection of Normal Control Groups from the Literature 
A. Normal controls for TRH stimulation of TSH 
Source 1: Journal of Clinical Endocrinology and Metabolism, 
vol. 34,1972,p.1076. Presents reponses of 12 normal females 
to 200 micrograms of TRH. Although only 100 micrograms of 
TRH was used in the present study, it is well known that the 
96 
two doses are almost equivalent 
Source 2: Journal of Clinical Endocrinology and Metabolism, 
vol. 40,1975,p.712. Presents responses of 15 normal females 
to 100 micrograms of TRH. 
Pooled results for the grand mean (GM), standard error of the 
grand mean(SEGM), and 2 standard deviations (2 SD), equivalent 
to a confidence limit of 95;o . 
time 6 15 30 45 60 90 120 
GM 2.6 15 16. 8 14.2 11.6 8.3 6.2 
SEGM .7 2.5 1.6 1.5 1.5 1.1 .9 
2 SD 7.1 9.7 16 15.5 15.2 11.0 9.3 
B. Normal controls for TRH stimulation of PRL 
Source 1: Journal of Clinical Endocrinology and Metabolism, 
vol. 41,1975,p.985. Presents responses of 10 normal males 
to 100 micrograms of TRH. 
Source 2: unpublished data from Dr. Gerard N. Burrow. 
Pooled results for the grand mean (GM), standard error of the 
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grand mean (SEGM), and 2 standard deviation (2 SD), equivalent 
to a confidence limit of 95%. 
time 0 15 30 45 60 90 120 
GM . 19.8 38.4 36.8 34.7 28.9 24.1 20.2 
SEGM .9 3.1 1.7 2.3 1.9 1.4 1.2 
2 SD 8.2 16.7 14.7 19.6 16.2 12.6 10.7 
C. Normal controls for insulin hypoglycemia stimulation of cortisol 
Source 1: Journal of Clinical Endocrinology and Metabolism, 
vol 40,1975,p.442. Presents the responses of cortisol to a mean 
hypoglycemia of 28 mg/dl. in 16 normal males. 
Source 2: Journal of ,Clinical Endocrinology and Metabolism, 
vol. 34, 1972,p. 895. Presents the responses of cortisol to 
a mean hypoglycemia of 30 mg/dl. in five normal patients. 
Source 3: Journal of Clinical Endocrinology and Metabolism, 
vol. 38,1974,p.836. Presents the responses of cortisol to 
a mean hypoglycemia of 25 mg/dl. in 13 normal patients, 8 
males and 5 females. 
Pooled results for the grand mean (GM), the standard error of 
the grand mean (SEGM), and 2 standard deviations(2 SD), 
equivalent to a confidence limit of 95%. 
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time 0 30 45 60 90 120 
GM 11 13.5 18.8 21.3 19.1 15.9 
SEGM .7 .8 .7 1.1 1.1 1.0 
2 SD 8.2 8.7 8.4 13.2 13.3 11.6 
D• Normal controls for insulin hypoglycemia stimulation of GH 
Source 1: New England Journal of Medicine, vol. 289,1973,p.236 
Presents the responses of GH to a mean hypoglycemia of 40 mg/dl. 
in 8 normal patients, 4 females and 4 males. 
Source 2: Journal of Clinical Endocrinology and Metabolism, 
vol 40,1975,p.442. Presents the responses of GH to a mean 
hypoglycemia of 28 mg/dl. in 16 normal males. 
Source 3: American Journal of Obstetrics and Gynecology, 
April 15, 1975,p.1103. Presents the responses of GH to a 
mean hypoglycemia of 25 mg/dl. in five normal patients, 
3 males and 2 females. 
Source 4: Journal of Clinical Endocrinology and Metabolism, 
vol. 34,1972,p.895. Presents the responses of GH to a mean 
hypoglycemia of 32 mg/dl. in five normal patients. 
Pooled results for the grand mean (GM), standard error of the 
grand mean (SEGM), and 2 standard deviations (2 SD), eguivalent 
to a.confidence limit of 95/. 
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time 0 30 45 60 90 120 
GM 1.9 10.7 25.2 30.1 28.4 22.3 
SEGM .5 5.8 2.4 3.6 3.7 3.2 
2 SD 6.3 25.8 28.5 42.4 43.4 36.8 
E. Normal controls for insulin hypoglycemia stimulation of PRL 
Source 1s Journal of Clinical Endocrinology and Metabolism, 
vol. 40,1975,p.442. Presents the responses of PRL to a mean 
hypoglycemia of 28 mg/dl. in 16 normal males. Results are 
presented in milliunits/ml. and have been expressed as 
percentage increase above baseline for comparison with 
patients in present study. 
Results for mean and SSM expressed as percentage increase 
above baseline. 
time 0_30 45 60 90 120 
mean % 0 33 133 112 100 67 
increase 
SEM % 20 30 50 30 45 30 
increase 
The baseline for the 13 patients in this study is then used 
as a comparative baseline for Figure 5 and Figure 6. 
F. Normal controls for insulin hypoglycemia stimulation of TSH 
No data available. 
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Formulae for calculations of the grand mean (GM), standard 
error of the grand mean (SEGM), and standard deviation of a 
single observation (SD). NB: E= sum (equivalent to sigma) 
n=number of items in sample x=mean of items in sample 
S—= SEM for items in sample 
X 
Samples 
Calculation of GM(x) 
= .E. n,x. 
x - 1=1 1 1 
E n. 
l 










(n^l) S2Xi + (n2-l) S2X2 + (n3-l) S2X3 + (ng-DS2^ 
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SUMMARY 
Thirteen asymptomatic women with postpartum blood loss 
of 500 to 2000 ccs within the first ten days after delivery 
underwent evaluation of endocrine function of the anterior 
pituitary gland. Insulin tolerance tests and TRH stimulation 
tests for measurement of serum levels of growth hormone, 
cortisol, prolactin, and thyrotropin were performed. There 
was no laboratory evidence of pituitary dysfunction in this 
group of thirteen patients. It appears that anterior 
hypopituitarism secondary to postpartum hemorrhage is 
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